Drug Trial Radar · NCT05084989
Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
948
Actual
Start
Jan 31, 2022
Primary completion
Aug 18, 2022
Study completion Feb 9, 2023
Sponsor
- Lead sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1: Primary Vaccination in Adults Part 1 will evaluate the safety and immunogenicity of the recombinant two component COVID-19 vaccine (CHO cell) (ReCOV for short) in adults aged 18 years and older, when administered as 2 intramuscular doses, 21 days apart. Part 2: Booster Vaccination in Adults Part 2 will evaluate the immunogenicity and safety and of one booster dose of ReCOV in adult participants who have received primary vaccination with 2 doses of an inactivated COVID-19 vaccine (CoronaVac®). COMIRNATY®, an mRNA COVID-19 vaccine will be used as the active control.
Conditions
- COVID-19
Interventions
Part1:Recombinant two-component COVID-19 vaccine (CHO cell)Biological
2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
Part1: PlaceboBiological
2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
Part2: Recombinant two-component COVID-19 vaccine (CHO cell)Biological
1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
Part2: COVID-19 Vaccine, mRNABiological
1 dose. Intramuscular injection, 30 μg/0.3 mL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part1, Primary SafetyTime frame: Day 7 after first dose and up to Day 28 after second dose
- Part1, Primary immunogenicityTime frame: 14 days after 2 doses vaccination
- Part2, Primary immunogenicityTime frame: 14 days after 2 doses vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Health Centrum
Roxas City, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.